| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Cholest-5-ene-3β,22(S)-diol targets lipid metabolism pathways. As an oxysterol, it may act as a ligand for nuclear receptors such as liver X receptors (LXRs) or other oxysterol-sensing proteins involved in cholesterol homeostasis. The compound targets ATP-binding cassette (ABC) transporters, which are involved in cholesterol efflux and lipid metabolism. Its effects on weight gain and serum TAG levels suggest activity on metabolic regulation pathways.
|
|---|---|
| ln Vitro |
U937 cell phosphatidylserine externalization, mitochondrial transmembrane potential, and cellular propidium iodide passage are all impacted by cholest-5-ene-3ß,22(S)-diol (10 μg/mL, 20 μg/mL; 24 h). Nuclear morphological alterations and permeability are inert [1].
In vitro, Cholest-5-ene-3β,22(S)-diol has no significant cytotoxic, oxidative, or inflammatory effects on human pronuclear leukemia cells. This favorable safety profile makes it suitable for research applications. The compound is an oxysterol with biological activity. As a potential LXR ligand, it may modulate gene expression in cell-based assays. However, detailed in vitro activity data including EC₅₀ values are not extensively published. |
| ln Vivo |
Triacylglycerols (TAG) caused by an increase in high-fat diet levels are eliminated and weight gain is decreased when cholest-5-ene-3ß,22(S)-diol (30 mg/kg; oral; on additional diet for 3 weeks) is taken[2]. The pharmacokinetic analysis of rats[2] includes the following parameters: route dose (mg/kg), Cmax (ng/mL), Tmax (h), AUCt (ng·h/mL), AUC (ng·h/mL), T1/2 (h), and Extent of tritium exchange (%).
In vivo, Cholest-5-ene-3β,22(S)-diol inhibits weight gain and increases serum triacylglycerol (TAG) levels in rat models. The compound is orally bioavailable, making it suitable for oral administration in animal studies. After 3 weeks of treatment, it increases gene expression of Ucp3 and Cpt2 in liver and skeletal muscle, and increases protein level of Ucp3 in skeletal muscle. These effects suggest activity on lipid metabolism and energy expenditure. |
| Enzyme Assay |
In vitro assays for Cholest-5-ene-3β,22(S)-diol typically involve evaluation of LXR activation using reporter gene assays in cells expressing LXRs. Cells are treated with the compound and LXR-responsive reporter activity is measured. Gene expression analysis by qPCR is used to measure expression of LXR target genes such as ABCA1, ABCG1, and SREBP-1c. Cytotoxicity is assessed using standard cell viability assays.
|
| Cell Assay |
In vitro cellular assays for Cholest-5-ene-3β,22(S)-diol typically involve evaluation of lipid metabolism in hepatocytes, macrophages, or other relevant cell types. Cells are treated with the compound and gene expression of lipid metabolism-related genes is measured by qPCR. Lipid accumulation can be assessed by Oil Red O staining or cholesterol efflux assays. Cytotoxicity is assessed using MTT or similar assays.
|
| Animal Protocol |
Animal/Disease Models: Male rats injected with Pentobarbital (20 mg, 50 mg/mL; ip)[2]
Doses: 30 mg/kg/day Route of Administration: Oral gavage; 3 weeks consecutively Experimental Results: diminished body weight gain Dramatically after 1 week treatment. Increased gene expression of Ucp3 and Cpt2 in liver and skeletal muscle, and increased protein level of Ucp3 in skeletal muscle after 3 weeks treatment. In vivo animal experiments for Cholest-5-ene-3β,22(S)-diol typically involve rat models. The compound is administered orally for 3 weeks. Endpoints include body weight measurement, serum TAG levels, and tissue gene expression analysis (Ucp3 and Cpt2 in liver and skeletal muscle). Protein levels (Ucp3) are measured by Western blot. The compound is orally bioavailable. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cholest-5-ene-3β,22(S)-diol are characteristic of oxysterols. The compound has a molecular weight of 402.65 g/mol and molecular formula C₂₇H₄₆O₂. It is orally bioavailable, indicating good absorption and sufficient metabolic stability for oral administration. As a lipophilic sterol, it is expected to have extensive tissue distribution. Purity is ≥98%.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Cholest-5-ene-3β,22(S)-diol is favorable. The compound has no significant cytotoxic, oxidative, or inflammatory effects on human pronuclear leukemia cells. This suggests a low toxicity profile at relevant concentrations. However, comprehensive toxicological evaluations including acute toxicity and repeated-dose studies have not been extensively reported. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Lemaire-Ewing S, et al. Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol Toxicol. 2005 Mar;21(2):97-114.
[2]. Tranheim Kase E, et al. Dietary supplementation with 22-S-hydroxycholesterol to rats reduces body weight gain and the accumulation of liver triacylglycerol. Lipids. 2012 May;47(5):483-93. |
| Additional Infomation |
(22S)-22-hydroxycholesterol is an oxosterol, a 22S-hydroxy derivative of cholesterol. It is a 22-hydroxy steroid, an oxosterol, and a 3β-hydroxy-Δ(5)-steroid. It is functionally associated with cholesterol.
Cholest-5-ene-3β,22(S)-diol (CAS# 22348-64-7, molecular formula C₂₇H₄₆O₂, molecular weight 402.65) is an orally bioavailable oxysterol. It inhibits weight gain and increases serum TAG levels in rats, increases Ucp3 and Cpt2 expression, and targets LXR and ABC transporters. No clinical trials or regulatory approvals have been identified. Purity: ≥98%. |
| Molecular Formula |
C27H46O2
|
|---|---|
| Molecular Weight |
402.65294
|
| Exact Mass |
402.35
|
| CAS # |
22348-64-7
|
| Related CAS # |
Cholest-5-ene-3ß,22(S)-diol-d7;1246302-91-9
|
| PubChem CID |
168038
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
6.359
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
CC(C)CC[C@@H]([C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O)O
|
| InChi Key |
RZPAXNJLEKLXNO-QUOSNDFLSA-N
|
| InChi Code |
InChI=1S/C27H46O2/c1-17(2)6-11-25(29)18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20-,21-,22+,23-,24-,25-,26-,27+/m0/s1
|
| Chemical Name |
(3S,8S,9S,10R,13S,14S,17R)-17-[(2S,3S)-3-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4835 mL | 12.4177 mL | 24.8355 mL | |
| 5 mM | 0.4967 mL | 2.4835 mL | 4.9671 mL | |
| 10 mM | 0.2484 mL | 1.2418 mL | 2.4835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
